FDA Grants Oncolyze Orphan Drug Designation for Leukemia Treatment

News
Article

FDA granted Oncoloze’s OM-301 an orphan drug designation for the treatment of acute myeloid leukemia (AML).

Oncolyze, a biopharmaceutical company specializing in cancer therapeutics, announced on Jan. 5, 2022, that FDA has granted the company an orphan drug designation. The designation was granted to the company’s preclinical drug candidate, OM-301, for acute myeloid leukemia (AML).

OM-301 is a therapeutic in pre-clinical development intended for the treatment of blood cancers. Acute myeloid leukemia is a rare form of cancer that has approximately 20,000 new cases each year, according to a company press release.

"We are actively fundraising to advance OM-301 into clinical trials. The orphan drug designation is an important milestone that further validates our efforts to investigate the value of OM-301 as a potentially groundbreaking therapy for patients with AML and other cancers," said Steven Evans, co-founder and CEO of Oncolyze, in the press release.

Source: Oncolyze

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes